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Background: Although progress in children, in adults, ALL still carries a dismal outcome. Here, we explored the
in vitro and in vivo activity of PF-00477736 (Pfizer), a potent, selective ATP-competitive small-molecule inhibitor of
checkpoint kinase 1 (Chk1) and with lower efficacy of checkpoint kinase 2 (Chk2).
Methods: The effectiveness of PF-00477736 as single agent in B-/T-ALL was evaluated in vitro and in vivo studies as a
single agent. The efficacy of the compound in terms of cytotoxicity, induction of apoptosis, and changes in gene and
protein expression was assessed using different B-/T-ALL cell lines. Finally, the action of PF-00477736 was assessed in vivo
using leukemic mouse generated by a single administration of the tumorigenic agent N-ethyl-N-nitrosourea.
Results: Chk1 and Chk2 are overexpressed concomitant with the presence of genetic damage as suggested by the
nuclear labeling for γ-H2A.X (Ser139) in 68 % of ALL patients. In human B- and T-ALL cell lines, inhibition of Chk1/2 as a
single treatment strategy efficiently triggered the Chk1-Cdc25-Cdc2 pathway resulting in a dose- and time-dependent
cytotoxicity, induction of apoptosis, and increased DNA damage. Moreover, treatment with PF-00477736 showed
efficacy ex vivo in primary leukemic blasts separated from 14 adult ALL patients and in vivo in mice transplanted with
T-ALL, arguing in favor of its future clinical evaluation in leukemia.
Conclusions: In vitro, ex vivo, and in vivo results support the inhibition of Chk1 as a new therapeutic strategy in acute
lymphoblastic leukemia, and they provide a strong rationale for its future clinical investigation.
Keywords: Acute lymphoblastic leukemia, DNA damage, Checkpoint kinase, Drug-sensitivity, New targetsBackground
Acute lymphoblastic leukemia represents a biologically
and clinically heterogeneous group of B/T-precursor-stage
lymphoid cell malignancies arising from genetic insults
that block lymphoid differentiation and drive aberrant cell
proliferation and survival. Survival rates for children are
approximately 80–85 % with current risk-oriented treat-
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ALL is heterogeneous, many achieve lasting second re-
missions. In contrast, survival after relapse in adult
ALL is short [4, 5]. New therapeutic strategies are there-
fore needed to improve remission rates in adults and to
prevent relapse both in adult and pediatric ALL patients.
Recently, in order to enhance DNA-damaging effects
inflicted by cytotoxic drugs or radiation, different check-
point kinase (Chk) inhibitors have been developed and
assessed alone or in combination with DNA-damaging
agents in preclinical studies and in phase I/II trials for
cancer therapy [6–14]. Some of them inhibit both Chk1
and Chk2; others have a higher specificity for Chk1. Thecle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Chk1 inhibitors and preliminary data deriving from early
clinical trials have been recently well reviewed in [15]. Fol-
lowing DNA damage, multiprotein complexes recruit the
transducers ataxia telangiectasia mutated (ATM) and
ataxia telangiectasia and Rad3-related protein (ATR) which
activate Chk2 and Chk1, respectively, despite an existing
extensive crosstalk between the ATR-Chk1 and ATM-
Chk2 pathways. Once activated by phosphorylation at
S317/S345 in response to DNA single strand breaks, Chk1
phosphorylates the phosphatase Cdc25A at the G1/S and S
phase checkpoints preventing cells from entering S phase
and Cdc25A and Cdc25C at the G2/M checkpoint avoid-
ing the entry in mitosis [16–19]. If Chk1 is induced by sin-
gle strand breaks, Chk2 activation is largely restricted to
DNA double strand breaks via ATM [20]. Once activated,
they mediate cell cycle delay, DNA repair, and apoptosis in
response to DNA damage. Moreover, Chk1 is required for
proper mitotic spindle assembly and maintenance of
chromosomal stability during mitosis [21].
PF-00477736 is a potent, selective, ATP-competitive,
small-molecule inhibitor of Chk1, synthesized by Pfizer,
which is selective for Chk1 and shows general selectivity
over other kinases [6]. Preclinically, PF-00477736 enhanced
docetaxel activity in tumor cells and xenografts by abrogat-
ing the mitotic spindle checkpoint, as well as the DNA
damage checkpoint [10]. The checkpoint abrogating and
cytotoxic activities attributed to PF-00477736 in combin-
ation with chemotherapy agents (e.g., gemcitabine and car-
boplatin) showed selectivity for p53-defective cancer cell
lines over p53-competent normal cells in vitro [6]. In xeno-
grafts, PF-00477736 enhanced the antitumor activity of
gemcitabine in a dose-dependent manner. PF-00477736
combinations were well tolerated with no exacerbation
of side effects commonly associated with cytotoxic
agents [6].
In this study, we investigated the activity of PF-0477736,
as a single agent, in B-/T-ALL by the following: assessment
of the in vitro efficacy in ALL cell lines and primary blast
cells, assessment of the in vivo efficacy in mouse models,
and identification and validation of potential biomarkers of
functional inhibition. Results demonstrated that in vitro
treatment of B-/T-ALL cell lines and primary blast cells
with PF-0477736 resulted in inhibition of cell viability,
induction of DNA damage, and apoptosis. Moreover,
in vivo studies confirmed the efficacy of Chk1 inhib-
ition, suggesting that this therapeutic strategy may be
promising in leukemia.
Results
Chk1 and Chk2 are overexpressed in acute lymphoblastic
leukemia
Chk1/2 transcript levels were assessed by quantitative
polymerase chain reaction (qPCR) in eight cell lines fromB/T-ALL (BV-173, SUP-B15, REH, NALM-6, NALM-19,
MOLT-4, RPMI-8402, and CCRF-CEM) (Additional file 1:
Figure S1) and in blast cells from 54 adult newly diag-
nosed ALL cases including 41 (76 %) BCR-ABL1-positive
and 13 (23 %) BCR-ABL1-negative cases. Normal bone
marrow precursor cells isolated from leukemia patients in
complete remission were also analyzed by the same
method. In this cohort, higher transcript levels of Chk1
but not Chk2 were found in leukemia cell lines and newly
diagnosed ALL cases compared to normal bone marrow
mononuclear cells (p value <0.001) (Fig. 1). The web-
based public database Oncomine [22] (https://www.onco-
mine.org/) was queried for Chk1/2 expression in the avail-
able leukemia datasets based on the comparison leukemia
versus normal using a criterion of a twofold change for
both Chk1 and Chk2 expressions and a p value of 1 × 10−4.
Using these stringent criteria, we found that both Chk1
and Chk2 transcripts are highly overexpressed in B-ALL
and T-ALL if compared to normal bone marrow samples
(Additional file 1: Figure S2). We then investigated by im-
munohistochemistry of formalin-fixed paraffin-embedded
(FFPE) tissue samples collected at diagnosis from 60 ALL
patients (36 B-ALL and 24 T-ALL) for protein expression
of Chk1, phosphorylated Chk1 (Ser345), Chk2, phosphory-
lated Chk2 (Thr68), Cdc25C, phosphorylated Cdc25C (Ser
2016), and phosphorylated H2A.X (Ser139) (γ-H2A.X). Re-
sults are detailed in Table 1 and viewed in Fig. 1c. Among
B/T-ALL, a diffuse positivity for Chk1, Chk2, Cdc25c, and
the phosphorylated forms of Chk1 (Ser345) and Cdc25c
(Ser216) was observed; these were detected in 51/54
(96 %), 55/57 (94 %), 57/57 (100 %), 45/56 (80 %), and 38/
55 (70 %) of the cases, respectively, whereas 15/55 (27 %)
of ALLs was stained for phosphorylated form of Chk2
(Thr68) (Fig. 1d). Interestingly, in our ALL series, genomic
damage was suggested by the nuclear labeling for γ-H2A.X
molecule in 40/59 (68 %) of samples (Fig. 1d). In thymuses,
normal lymphoblasts did not show protein expression of
Chk1, Chk2, Cdc25C, and their phosphorylated counter-
parts (Fig. 1d). In B follicles of the reactive lymph node, in
spite of the Chk1 weak positivity, diffuse Chk2, and
Cdc25C nuclear staining, no phosphorylation in their
amino acid Ser345, Thr68, and Ser216, respectively, was
detected (Fig. 1d). Notably, in thymuses and reactive B fol-
licles, only scattered γ-H2A.X+ cells were present, indicat-
ing a low level of genomic damage in physiologic
conditions compared to ALLs (Fig. 1d).
PF-00477736 reduces cell viability in a dose-dependent
manner
B-/T-ALL cell lines were incubated with increasing con-
centrations of drug (5–1000 nM) for 24 and 48 h. PF-
00477736 inhibition resulted in dose- and time-dependent
cytotoxicity with RPMI-8402 (T-ALL) being the most sen-
sitive (IC50 = 57.4 nM at 24 h) while NALM-6 (B-ALL)
Fig. 1 Chk1 (a) and Chk2 (b) mRNA expression levels in leukemia cell lines (BV-173, SUP-B15, REH, NALM-6, NALM-19, MOLT-4, RPMI-8402, and
CCRF-CEM), blast cells from 54 adult newly-diagnosed ALL cases, and in normal bone marrow mononuclear cells (MNC). Results are expressed as
Log10 2exp[−(ΔΔCt)], and they are the mean of at least two different replicates. c Immunohistochemical profile of the 60 ALL (36 B-ALL and
24 T-ALL); a red box indicates expression of the marker, whereas a green box signifies negativity (samples were considered positive if 30 % or
more of the cells were stained with an antibody); gray box indicates a not evaluable reaction due to a core loss in TMA. The figure allows the
assessment of the co-expression of the DNA damage markers in individual samples. d Immunohistochemical expression of Chk1, phosphorylated
Chk1 (Ser345), Chk2, phosphorylated Chk2 (Thr68), and phosphorylated H2A.X (Ser139) (γ-H2A.X) in thymus, reactive follicle (RF), T-ALL and
B-ALL. The figure highlights the close similarity between expression profiling of B- and T-ALL, characterized by a high percentage of cases Chk1+,
pChk1+, Chk2+, Cdc25C, pCdc25C, pH2A.X+ and, in a lesser extent, pChk2+, and its distinction with the expression profiling of the non-tumoral
populations as maturing thymocytes, which were substantially negative for these seven proteins and as B lymphocytes of reactive follicles, which
resulted Chk1 weakly +, Chk2+, Cdc25C+ but negative for the corresponding phosphorylated forms and pH2A.X. (a) Thymus: thymocytes
Chk1− (×400); (b) RF: B lymphocytes in mantle zone (MZ) and germinal center (GC) showing weak Chk1 positivity (×100); (c) strong expression of
Chk1 in T-ALL; and (d) B-ALL (×400). (e) Thymus: thymocytes pChk1− (×400); (f ) RF: B lymphocytes in MZ and GC pChk1−; (g) strong positivity of
pChk1 in T-ALL; and (h) B-ALL (×400). (i) Thymus: normal lymphoblasts Chk2− (×400); (j) RF: B lymphocytes in MZ and GC showing diffuse Chk2
positivity (×100); (k) strong nuclear staining for Chk2 in T-ALL; and (l) B-ALL (×400). (m) Thymus: thymocytes pChk2− (×400); (n) RF: B lymphocytes
in MZ and GC pChk2− (×100); (o) diffuse expression of pChk2 in T-ALL; and (p) B-ALL (×400). (q) Thymus: normal lymphoblasts negative for Cdc25C
(×400); (r) RF: B lymphocytes in mantle zone (MZ) and germinal center (GC) showing weak Cdc25C positivity (×100); (s) strong nuclear staining for
Cdc25C in T-ALL; and (t) B-ALL (×400). (u) Thymus: thymocytes pCdc25C− (×400); (v) RF: B lymphocytes in MZ and GC pCdc25C− (×100); (w) diffuse
expression of pCdc25C in T-ALL; and (x) B-ALL (×400); (y) Thymus: normal lymphoblasts negative for pH2A.X (γ-H2A.X) (×400); (z) RF: MZ B and GC
lymphocytes substantially pH2A.X (γ-H2A.X)-negative, with only occasional GC positive cells (×100); (aa) strong nuclear staining for pH2A.X (γ-H2A.X)
in T-ALL; and (ab) B-ALL (×400)
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Table 1 Immunohistochemical results
Tumor
type
Chk1 pChk1 Chk2 pChk2 Cdc25C pCDc25C γH2A.X
pos (%) pos (%) pos (%) pos (%) pos (%) Pos (%) pos (%)
ALL 51/54 (94) 45/56 (80) 55/57 (96) 15/55 (27) 57/57 (100) 38/55 (70) 40/59 (68)
B-ALL 31/31 (100) 28/33 (85) 32/33 (97) 11/32 (33) 34/34 (100) 23/32 (72) 25/36 (69)
T-ALL 20/23 (87) 17/23 (74) 23/24 (96) 4/23 (17) 23/23 (100) 15/23 (65) 15/23 (65)
pos number of positive cases/number of evaluable cases
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sitivity does not correlate with leukemia cell type (B-ALL
vs T-ALL), TP53 mutation status (BV-173, SUPB-15,
NALM-6, and NALM-19 cells were p53 wild-type,
whereas REH, MOLT-4, RPMI-8402, and CEM cells were
p53 mutated) (Fig. 2a), and with baseline levels of Chk1/2
and ATR/ATM phosphorylation, indicative of intrinsic
genetic stress (Fig. 2b).
PF-00477736 induces apoptosis at 24 and 48 h in B-/T-ALL
cells
In order to assess whether cytotoxicity was correlated to
increased susceptibility to apoptosis, B-/T-ALL cell lines
were incubated with increasing concentrations of drug
(0.1, 0.5, and 1 μM and 0.05, 0.1, and 0.2 μM only for
BV-173 and RPMI-8402, respectively) for 24 and 48 h.
Consistent with the viability results, Annexin V/propi-
dium iodide (PI) staining analysis showed a significant
increase of apoptosis at 24 and 48 h in B- and T-ALL
cells proportional to drug dose and drug exposure times
(Additional file 1: Figure S3-A). The induction of apop-
tosis by PF-00477736 was also assessed by the detection
of poly (ADP-ribose) polymerase (PARP) cleavage by
Western blot analysis [23]. The PARP-1 cleavage band at
89 kDa was observed in lysates from leukemia cell lines
after 24 h of drug exposure, while it was undetectable in
cells treated with only DMSO 0.1 % (Fig. 2c).
PF-00477736 perturbs the cell cycle profile in B-/T-ALL cells
The effect of the inhibition of Chk1 pathway on cell
cycle progression was evaluated in RPMI-8402, BV-173,
SUP-B15, and NALM-6 cell lines. Cells were incubated
with increasing concentrations of PF-00477736 for 6 and
24 h and then stained with propidium iodide to quantify
the DNA amount. The effect of PF-00477736 on the cell
cycle progression was very weak after 6 h of incubation
(data not showed) and very heterogeneous among the
different cell lines after 24 h. In RPMI-8402, BV-173,
and SUP-B15 cell lines, the treatment induced a progres-
sive reduction of the number of cells in S and G2/M
phase and a concomitant increment of cell debris. In the
less sensitive cell line, NALM-6, the inhibition of Chk1
progressively increased the percentage of cells in G2/M
phase and reduced the percentage of cells in G1 phase
(Additional file 1: Figure S3-B).PF-00477736 efficiently targets Chk1 pathway and induces
DNA damage
In order to assess whether PF-00477736 efficiently targeted
Chk1 pathway, we examined the changes in the down-
stream phosphorylation of the phosphatase Cdc25C and
cyclin-dependent kinase, Cdc2. Moreover, Chk1 itself and
γ-H2A.X, which is a marker of stalling replication forks
and checkpoint abrogation-induced apoptosis, have been
assessed. Functional analyses were initially performed on
the most sensitive (BV-173) and the most resistant
(NALM-6) B-ALL cell lines, as determined by the viability
and apoptosis analyses. Specifically, BV-173 cells were
treated with 0.05, 0.1, and 0.2 μM and NALM-6 with 0.1,
0.5, and 1 μM of PF-00477736 for 24 h (Fig. 3a). In the sec-
ond analysis, BV-173 and NALM-6 cells were treated with
the dose of PF-00477736 that goes near to the IC50
(0.1 μM for BV-173 and 1 μM for NALM-6) for 18, 24, 30,
and 48 h (Fig. 3b). Thereafter, the same molecular targets
have been assessed on all B- and T-ALL cell lines using the
dose that goes near to the IC50 (Additional file 1: Figure
S4). Active Chk1 phosphorylates Cdc25C at serine 216
throughout the interphase and upon G2 checkpoint activa-
tion. This leads to the nuclear export of Cdc25C and its
subsequent cytoplasmic sequestration by 14-3-3 protein,
which prevents the activation of the downstream target of
Cdc25C, the cyclin B/Cdc2 kinase that is responsible for
G2/M transition [24]. Upon inhibition of Chk1, we ob-
served decreased levels of phosphorylated Cdc25c (Ser216)
and Cdc2 (Tyr 15) as well as reduced levels of their total
forms in a dose- and time-dependent manner, suggesting
that PF-00477736 efficiently targets Chk1 pathway. In con-
trast, the phosphorylated forms of Chk1 (Ser317 and
Ser345) were dose-dependently increased suggesting that
treatment amplifies genomic damage which in a feedback
loop increases Chk1 phosphorylation. Although the incre-
ment of the phosphorylated forms of Chk1 (Ser317 and
Ser345) as a consequence of genomic damage amplifica-
tion, the complete inhibition of Chk1 functionality was
confirmed by the progressive reduction of the auto-
phosphorylated form of Chk1 (Ser296) in an early time
point analysis. Indeed, even after 3 h of treatment with PF-
00477736 in both BV-173 and NALM-6 cell lines, the
auto-phosphorylated form of Chk1 (Ser296) was drastically
reduced in comparison with the untreated counterpart
(Additional file 1: Figure S4-B). The enhancement of
Fig. 2 a IC50 values for B- and T-ALL cell lines at exposure durations of 24 and 48 h (hrs) to PF-0477736. For each cell line, the mutational status
of TP53 gene is shown. Abbreviations: WT wild-type; hrs hours. b Assessment of the expression and activation of the major components of the
ATR-Chk1 and ATM-Chk2 pathways in B-/T-ALL cell lines at baseline. The homogeneity of the protein loaded was determined by using as an
internal control (β-actin). c Reduction of PARP-1 cleavage in leukemia cell lines detected by Western blotting. PARP-1 cleavage was detected as a
marker of apoptosis. Β-actin was detected on the same membrane for loading normalization
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Fig. 3 (See legend on next page.)
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Fig. 3 a Western blot analysis in BV-173 and NALM-6 cell lines after exposure to increasing concentrations of PF-00477736 (0.05, 0.1, and 0.2 uM
for BV-173 and 0.1, 0.5, and 1 uM for NALM-6) or DMSO 0.1 % (−). b Western blot analysis in BV-173 and NALM-6 cell lines after exposure to
PF-00477736 (+) at the concentration closest the IC50 or DMSO 0.1 % (−) at 18, 24, 30, and 48 h. c Western blot analysis in all leukemia cell lines
after exposure to PF-00477736 (+) at the concentration closest the IC50 or DMSO 0.1 %
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dependently increase of γ-H2A.X both in Western blot
and immunofluorescence analyses.
The phospho-H2A.X accumulates and forms character-
istic nuclear foci where the DNA is damaged [25]. Both
NALM-6 and BV-173 cell lines show an increased number
of γ-H2A.X foci when treated with PF-00477736 com-
pared to untreated controls (Fig. 3c). However, evaluating
the mean fluorescence intensity of γ-H2A.X positive cells,
BV-173 cells seem to be more damaged than NALM-6.
Actually, BV-173 treated cells have five-fold change differ-
ence of mean value intensity of γ-H2A.X compared to
BV-173 untreated cells, while NALM-6 treated cells have
1.4-fold change difference of mean value intensity of γ-
H2A.X compared to their untreated counterparts. In
addition to these changes in the overall amount of γ-
H2A.X foci among the two different cell types, we ob-
served the presence of hyper-γ-H2A.X-positive cells
specifically in BV-173 cells treated with PF-00477736.
The so-called hyper-γ-H2A.X-positive cells loose the
typical foci signal of γ-H2A.X and emit a much higher
and diffuse signal of γ-H2A.X positivity. Almost 6.5 %
of the γ-H2A.X-positive cells are hyper-γ-H2A.X-posi-
tive in BV-176-treated cells compared to 1.8 % in the
untreated controls. These data suggest a higher induc-
tion of DNA damage upon PF-00477736 treatment in
BV-173 than NALM-6 cells as expected by the fact that
BV-173 cells are more responsive to PF-00477736.
However, the increase of hyper-γ-H2A.X-positive cells
only in BV-176-treated cells would suggest the exist-
ence of a specific effect that causes a hyper DNA dam-
age only in a restricted, but significant, population of
leukemic cells.
Interestingly, upon treatment, we observed a strong re-
duction of Chk1. As already hypothesized, this may be the
result of cleavage by caspase during apoptosis induced by
genotoxic stress [26, 27]. Persisting protein levels of
Cdc25, pChk1, Ser345, pCdc2 (Tyr 15), and Cdc2 after
48 h of exposure to PF-00477736 differentiated less sensi-
tive leukemia cells from more sensitive ones (Additional
file 1: Figure S3c).
Gene expression profiling results
In order to identify gene expression changes specifically
correlated with Chk1 inhibition and to better elucidate the
mechanism of action of Chk1 inhibitor, gene expression
profiling (GEP) analysis was performed by microarray on
treated B/T-ALL cell lines (BV-173, SUP-B15, REH,NALM-6, NALM-19, MOLT-4, RPMI-8402, and CCRF-
CEM) and on their untreated counterparts (DMSO 0.1 %)
after 24 h of drug exposure. Treatment resulted in a differ-
ential expression of 941 genes (p < 0.05): 528 (56 %) were
down-modulated and 413 (44 %) were upregulated in
treated leukemia cells compared to untreated cells
(Additional file 2 and Fig. 4). To identify peculiar critical
pathways affected by Chk1 inhibition, the differentially
expressed genes were analyzed in terms of biological func-
tion using the MetaCore pathway mapping software (Gen-
eGo Inc.) which categorizes genes in pathway maps, Gene
Ontology (GO) cellular processes, and cellular and mo-
lecular process networks. Consistent with a Chk1’s mech-
anism of action, the three top scored maps (map with the
lowest p value) were “cell cycle: estrogen receptor 1
(ESR1) regulation of G1/S transition” including c-Jun/c-
Fos, cyclin A, CARM1, Skp2/TrCP/FBXW, SKP2, c-Fos,
CDK4, NCOA3, c-Jun, and CDK2 genes (Additional file 1:
Figure S5); “apoptosis and survival: granzyme A signaling”
including PHAP1, Ku70/80, Ku80, Ku70, histone H3,
NDPK A, SET, histone H2B, and histone H1 genes
(Additional file 1: Figure S6); and “DNA damage: ATM/
ATR regulation of G1/S checkpoint” including PCNA,
growth arrest and DNA damage 45 alpha (GADD45a),
Chk2, cyclin A, NF-kB, cyclin-dependent kinase 4 (CDK4),
FANCD2, Claspin, and CDK2 genes (Additional file 1:
Figure S7). GO cellular processes highlighted 617 genes
involved in cellular metabolic process (Additional file 3).
Finally, the three top scored process networks impaired by
the treatment with Chk1 inhibitor were as follows: the
DNA damage checkpoint, the S phase of cell cycle, and
the apoptosis, confirming the specificity of treatment on
its target pathways (Additional file 4). Thirty-five genes
had a false discovery rate less than 0.05 (Additional file 5:
Table S1), and the three most differentially expressed
genes were as follows: DNA damage-inducible transcript
3 (DDIT3, fold-change 3.32, p value 6.06 × 10−5), Kruppel-
like factor 6 (KLF6, fold-change 2.17, p value 8.41 × 10−5),
and FBJ murine osteosarcoma viral oncogene homolog
(FOS, fold-change 2.40, p value 1.97 × 10−4). Due to its im-
plication in the regulation of the cell cycle and apoptosis,
Western blot analysis against c-Jun was performed to bet-
ter comprehend its biological role in response to PF-
00477736. c-Jun is a component of the transcription factor
activating protein-1 (AP-1) which is involved in cell cycle
progression through the G1 phase by the regulation of the
cyclin D1 [28]. As soon after treatment with Chk inhibitor,
c-Jun protein levels increased in all B-ALL cell lines but
Fig. 4 Heat map of differentially expressed genes. Lists of differentially expressed genes with a t test p value <0.05 were generated for each cell
line. A hierarchical clustering method in Partek Genomics Suite was used to construct both the gene tree and the sample tree. Data are shown in
a matrix format: each row represents a single gene, and each column represents a cell line. Red indicates overexpressed genes and blue indicates
underexpressed genes (see legend)
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treatment was very heterogeneous (Additional file 1:
Figure S8-A). The data found in the gene expression
profile analysis were validated using qPCR. Four genes
(two upregulated, PLK3 and GADD45a; two downregu-
lated, Chk2 and CDK4), which have been chosen on their
biological relevance in the Chk1 pathway, were validated
on B-/T-ALL cell lines treated for 24 h with or without
PF-00477736 (IC50) (Additional file 1: Figure S8-C).
PF-00477736 reduces viability in primary ALL blast cells
The efficacy of PF-00477736 was confirmed in primary
blast cells from 14 newly diagnosed cases including ten
BCR-ABL1-positive (71 %) cases and four BCR-ABL1-
negative ALL cases (29 %). Leukemic cells were incubated
with increasing concentrations of drug (0.1, 0.5, and
1 μM) for 24 h. Based on the viability results, three groups
of patients were identified: very good responders, 36 % (5/
14) with IC50 at 24 h ranging from 0.1 to 0.5 μM; good re-
sponders, 43 % (6/14) with IC50 at 24 h ranging from 0.5
to 1 μM; and poor responders, 21 % (3/14) with IC50 at
24 h higher than 1 μM (Additional file 5: Table S2 and
Fig. 5a). PF-00477736 did not reduce viability in primarycultures of normal bone marrow mononuclear cells, dem-
onstrating that it selectively targets leukemia cells (Fig. 5b).
Moreover, in contrast to leukemia cells, treatment did not
induce protein phosphorylation changes in Chk1 (Ser345),
Cdc25c (Ser216), and Cdc2 (Tyr 15) neither increased
levels of phospho-H2A.X (Additional file 1: Figure S8-B).
PF-00477736 impairs survival of leukemic mice
We extended the in vitro and ex-vivo studies by asses-
sing the efficacy of Chk inhibitor in mice transplanted
with T-ALL.
Leukemic mice were generated by the usage of the
tumorigenic agent N-ethyl-N-nitrosourea (ENU). The ob-
tained leukemia has been immunophenotyped and charac-
terized as a T-ALL. Leukemic blasts coming from the
spleen of leukemic animals were transplanted into C57BL/
6Ly5.1-recipient mice. Three days after transplantation, a
time sufficient for leukemic blasts to home the bone mar-
row of the host, we started to treat the animals. A concen-
tration of 40 mg/kg of PF-00477736 given with a q3dx4
schedule seems not to be toxic for the animals; however, it
significantly affects the overall survival of the treated ani-
mals (five mice) in comparison to the untreated ones
Fig. 5 (See legend on next page.)
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Fig. 5 a Cell viability results in primary ALL blast cells after 24 h of exposure to PF-0477736 at 100, 500, and 1000 nM. b Cell viability results in normal
bone marrow mononuclear cells after 24 h of exposure to PF-0477736 at 100, 500, and 1000 nM. c Survival curves of leukemic mice treated with
PF-0477736 and control mice injected with vehicle. PF-0477736 treatment significantly increases the overall survival of mice transplanted with murine
lymphoid leukemia (p value =0.0009)
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(intraperitoneally injected with PBS) die all at day 17 post-
transplantation while the animals treated with PF-00477736
live longer (up to 59 days post transplantation). The
leukemia used for the experiments shown here was very
aggressive (untreated animals die with massive infiltra-
tion of the spleen and the liver by leukemic blasts at
day 17) suggesting a reason why the effect of the Chk
inhibitor is significant though quite variable among
treated mice (Fig. 5c).
Discussion
Several studies in different tumors have investigated the
role of Chk inhibition in combination with conventional
chemotherapy demonstrating that this combination en-
hances tumor cell death [6, 10].
Here, we evaluated the in vitro and in vivo effects of the
administration of PF-00477736 as a single agent and not
in combination with other chemotherapeutic agents in cell
lines and primary blast cells from acute lymphoblastic
leukemia based on the hypothesis that the intrinsic gen-
omic instability of leukemic clones as demonstrated by the
nuclear labeling for γ-H2A.X molecule in 68 % of ALL pa-
tients may be itself sufficient to bring the cells to apop-
tosis. According to this hypothesis, it was possible to
highlight how the administration of PF-0477736 as single
agent was able to reduce cell viability in all leukemia cell
lines treated in this study (BV-173, SUP-B15, REH,
NALM-6, NALM-19, MOLT-4, RPMI-8402, and CCRF-
CEM) and to induce apoptosis (Fig. 6). Different leukemia
cell lines showed different sensitivity to PF-00477736 with
RPMI-8402 (T-ALL) being the most sensitive (IC50 = 57.4
at 24 h) while NALM-6 (B-ALL) the less sensitive (IC50 =
1423.0 at 24 h) cell line. Interestingly, the sensitivity to
Chk1 inhibitor was not related to the mutational status of
the tumor suppressor p53.
The results obtained on cell viability and induction of
apoptosis have been confirmed by genome-wide studies
evaluating global gene expression changes upon treatment
and by functional studies performed by Western blot ana-
lysis. Interestingly, by GEP analysis, the majority of genes
downregulated were involved in the DNA damages re-
sponse and in particular in DNA repair mechanisms,
while the genes upregulated were involved in chromatin
assembly, nucleosome organization, DNA packaging, and
apoptosis. The efficacy of Chk inhibition has been eval-
uated and confirmed in terms of reduction of cell via-
bility in primary ALL blast cells but not in normal bonemarrow precursor cells. Furthermore, assessing the effi-
cacy of Chk inhibition in mice transplanted with T-
lymphoid leukemia, we demonstrated that PF-0477736
increases the survival of treated mice compared with
mice treated with vehicle (p = 0.0016).
In conclusion, in vitro, ex-vivo, and in vivo results sup-
port the inhibition of Chk1 as a new therapeutic strategy in
acute lymphoblastic leukemia, and they provide a strong
rationale for its future clinical investigation. The check-
point kinase inhibitor have been synthetized to increase
the effectiveness of conventional chemotherapy, preventing
cells to arrest cell cycle, and to repair the DNA damages
caused by the exposure to genotoxic agents. Here, we high-
light that even the treatment with a checkpoint kinase in-
hibitor alone associated with the high genetic instability
can be enough to kill cancer cells. Indeed, we believe that
leukemic cells, thanks to a higher activation of the ATR-
Chk1/ATM-Chk2 pathways, can better tolerate high gen-
etic instability. Switching off these mechanisms of survive,
we can kill leukemic cell by overcoming the cell cycle
checkpoint, by inhibiting the mechanisms of DNA dam-
ages repair and by inducing massive damages that cannot
be tolerated (Fig. 6).
Conclusions
Inhibition of Chk1/2 represents a novel therapeutic
strategy to overcome genetic instability and to promote
selective killing of leukemia cells in ALL.
Methods
Leukemia cell lines
Human B- (BV-173, SUP-B15, REH, NALM-6, and
NALM-19), T-ALL (MOLT-4, RPMI-8402, and CCRF-
CEM) cell lines were obtained from Leibniz-Institut
DSMZ-Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (Germany). Cells were cultured in
RPMI-1640 medium (Invitrogen, Paisley, UK) with 1 %
L-glutamine (Sigma, St. Louis, MO, USA) and penicillin
and streptomycin (Gibco, Paisley, UK) supplemented with
10–20 % fetal bovine serum (Gibco) in a humidified atmos-
phere of 5 % CO2 at 37 °C. Online databases have been in-
terrogated to molecularly characterize leukemia cell lines:
International Agency for Research on Cancer (IARC) TP53
database (http://www-p53.iarc.fr/) and the Catalogue of
Somatic Mutations in Cancer, (COSMIC, http://www.san-
ger.ac.uk/genetics/CGP/cosmic/). The Chk1 inhibitor PF-
00477736 was purchased by Sigma-Aldrich (Sigma-Aldrich
Co. St. Louis, MO, USA).
Fig. 6 Cartoon drawing the rational of the study: in leukemia cells, oncogenes could lead to replication stress, activation of ATR/Chk1 pathway
that in conjunction with elevated proliferation promote tolerable level of DNA damage, genomic instability, and tumor progression. Inhibition of
Chk1/Chk2 could increase DNA damage leading to apoptosis
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The Chk inhibitor PF-00477736 was purchased from
Sigma-Aldrich (Sigma-Aldrich Co. St. Louis, Missouri
63103 United States). qPCR analysis of Chk1 and Chk2
mRNA expressions was evaluated in 41 (76 %) newly
diagnosed BCR-ABL1-positive (median age 56 years,
range 26–81; ratio male to female 20/21) and 13 (23 %)
newly diagnosed BCR-ABL1-negative ALL cases (median
age 41 years, range 18–69; ratio male to female 5/8). Onemicrogram of RNA was reverse transcribed using the
High-Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA, USA). PCR analysis was performed using
HS00967506_m1 (Chk1) and HS00200485_m1 (Chk2)
assays (Applied Biosystems) and the Fluidigm Dy-
namic Array 48 × 48 system, a real-time qPCR assay
which enables to automatically assemble 48 samples
and 48 assays to create individual TaqMan reactions of a
final volume of 6.75 nl each (Fluidigm, San Francisco, CA,
Iacobucci et al. Journal of Hematology & Oncology  (2015) 8:125 Page 12 of 15USA; http://www.fluidigm.com/). RNA integrity was con-
firmed by PCR amplification of the GAPDH mRNA
(Hs99999905_m1), which is expressed ubiquitously in
human hematopoietic cells. Results were expressed as
2exp(−ΔΔCt). GraphPad Prism 5 software (GraphPad,
Avenida de la Playa La Jolla, CA, USA) was used to plot
the data. The basal mRNA expression of Chk1 and of
Chk2 was evaluated in all the cell lines using the same
assays (Applied Biosystems: HS00967506_m1 Chk1 and
HS00200485_m1 Chk2) used for the primary samples,
and the statistical validity of the results were confirmed
using ANOVA multiple comparisons test (GraphPad
Prism 5 software). In addition, reverse transcription
and quantitative PCR analysis for GADD45a, PLK3,
CDK4, and CHK2 in treated cell lines and on their un-
treated counterpart was performed as described above
using the following assays from Applied Biosystems:
Hs00169255_m1 (GADD45a), Hs00177725_m1 (PLK3),
Hs00262861_m1 (CDK4), and HS00200485_m1 (Chk2).
TP53 mutation screening
Total cellular RNA was extracted using the RNeasy total
RNA isolation kit (Qiagen, Valencia, CA, USA). One
microgram of total RNA was reverse transcribed using the
M-MLV Reverse Transcriptase (Invitrogen, San Diego, CA,
USA). Three overlapping shorter amplicons [amplicon 1
(491 bp) exons 1–5; amplicon 2 (482 bp) exons 5–8; ampli-
con 3 (498 bp) exons 8–11)] covering the entire TP53 cod-
ing sequence [GenBank:NM_000546.4] were amplified
with 2 U of FastStart Taq DNA Polymerase (Roche Diag-
nostics, Mannheim, Germany), 0.8 mM dNTPs, 1 mM
MgCl2, and 0.2 M forward and reverse primers (Additional
file 5: Table S3) in 25 μl reaction volumes. PCR products
were purified using QIAquick PCR Purification Kit (Qia-
gen) and then directly sequenced using an ABI PRISM
3730 automated DNA sequencer (Applied Biosystems,
Foster City, CA, USA) and a Big Dye Terminator DNA se-
quencing kit (Applied Biosystems). All sequence variations
were detected by comparison using the BLAST software
tool (www.ncbi.nlm.nih.gov/BLAST/) to reference genome
sequence data [GenBank:NM_000546.4].
Immunohistochemistry
Studies evaluating Chk1, phosphorylated Chk1 (Ser345),
Chk2, phosphorylated Chk2 (Thr68) Cdc25C, phosphory-
lated Cdc25C (Ser216), and phosphorylated H2A.X
(Ser139) (γ-H2A.X) protein expressions were performed
on FFPE samples corresponding to three thymuses, three
reactive lymph nodes, and to primary tumors collected
from 60 ALL patients at diagnosis, including 36 B-ALL
(median age 50 years, range 5–86; ratio male to female 18/
18) and 24 T-ALL (median age 38 years, range 2–76; ratio
male to female 15/9). All the cases were retrieved from the
archives of the Haematopathology Unit, Department ofExperimental, Diagnostic and Specialty Medicine—DIMES,
University of Bologna. The study was conducted according
to the principles of the Declaration of Helsinki after ap-
proval of the Internal Review Board. Two different tissue
microarrays (TMAs) were constructed from these paraffin-
embedded blocks as previously reported. TMA sections
were investigated by antibodies raised against fixation re-
sistant epitopes. The antibody reactivity and sources as well
as the antigen retrieval protocols, dilutions, and revela-
tion systems are detailed in Additional file 5: Table S4.
A cutoff of staining >30 % of the examined cells was
assigned as positive score, according to formerly de-
fined criteria [29]. Immunohistochemical preparations
were visualized, and images were captured using Olym-
pus dotSlide microscope digital system equipped with
the VS110 image analysis software.
Primary cells
Primary blast cells from 14 newly diagnosed ALL cases
were obtained, upon written informed consent, from bone
marrow and peripheral blood samples by density gradient
centrifugation over Lymphoprep (Nycomed UK, Birming-
ham, UK). ten (71 %) samples were from adults with BCR-
ABL1-positive ALL (median age 51 years, range 25–74
years; median blast percentage 92 %, range 60–100 %) and
four (29 %) from patients with BCR-ABL1-negative ALL
(median age 34 years, range 18–43 years; median blast
percentage 93 %, range 90–100 %). Main patients’ charac-
teristics are given in Additional file 5: Table S1.
Normal bone marrow progenitors were harvested from
bone marrow aspirations performed in lymphoma patients
undergoing initial staging procedures, which then resulted
negative for lymphoma infiltration. Normal peripheral
blood progenitors were harvested from healthy donors.
Cell viability assay
In order to assess the cell viability after treatment with
PF-00477736 (Pfizer), ALL cell lines were seeded in 96-
well plates at 50,000 cell/100 μl/well with increasing
concentrations of drug (0.005–2 μM) for 24 and 48 h
and incubated at 37 °C. Cell viability was assessed by
adding WST-1 reagent (Roche Applied Science, Basel,
Switzerland) to the culture medium at 1:10 dilution.
Cells were incubated at 37 °C, and the optical density
was measured by microplate ELISA reader at λ = 450
after 3 h. The amount of the formazan formed directly
correlates to the number of metabolically active cells. All
viability experiments were performed in triplicates and
repeated in least two separated experiments. In ex-vivo
primary leukemia cells, the effects on cell viability were
assessed by counting viable and non-viable cell numbers
by the trypan blue dye exclusion method. Cells were
seeded in six-well plates at 500,000 cell/1 ml with in-
creasing concentrations of drug (0.1, 0.5, and 1 μM) for
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lated as a percentage of the viable cells compared to the
untreated controls (DMSO 0.1 %).
Annexin V staining of apoptotic cells
According to the WST-1 results, three different increas-
ing concentrations of PF-00477736 were used to treat
leukemia cells lines in order to detect and discriminate
apoptotic, necrotic and dead cells. Cell lines were seeded
in 12-well plates at 500,000 cell/1 ml with increasing
concentrations of drug (0.1, 0.5 and 1 μM and 0.05, 0.1
and 0.2 μM only for BV-173 and RPMI-8402) for 24 and
48 h and incubated at 37 °C. Following the treatment,
cells were harvested and stained with Annexin V/PI ac-
cording to the manufacturer’s instruction (Roche). The
percentage of Annexin V-PI-positive cells was deter-
mined within 1 × 104 cells of the population by flow cy-
tometry (FACSCanto II, BD Biosciences Pharmingen,
San Jose, CA, USA). The mean percentage of Annexin
V-PI-positive cells and standard error measurement was
calculated from at least two separate experiments.
Western blot analysis
To gain insight into the molecular mechanisms respon-
sible for cell death following treatment, functional analyses
by Western blot were performed. Leukemia cell lines were
plated in six-well plates at 500,000 cell/1 ml with increas-
ing concentrations of drug for 24 h and incubated at 37 °C.
After the treatment, the cells were collected and lysate
using a specific buffer made of KH2PO4 0.1 M (pH 7.5),
Igepal 1 % (NP-40), β-glicerofosfato 0.1 mM, and complete
protease inhibitor cocktail 1× (Roche Diagnostics). For
each sample, 30 μg of protein was fractioned on Mini-
PROTEAN TGX stain-free precasted gels, blotted to nitro-
cellulose membranes (Bio-Rad Trans-blot turbo transfer
pack), and incubated overnight with the following
antibodies: ATM (#2873S), phosphorylated ATM
(Ser1981)(#5883S), ATR (#2790S), phosphorylated ATR
(Ser428)(#2853S), Chk1 (#2345S), phosphorylated Chk1
(Ser317)(#2344S), phosphorylated Chk1 (Ser296)(#2349)
and Chk1 (Ser345)(#2348S), Chk2 (#2662S), phosphory-
lated Chk2 (Thr68)(#2661S), Cdc25c (#4688S), phosphory-
lated Cdc25C (Ser216)(#9528S), PARP-1 (#9542), Cdc2
(#9112S), phosphorylated Cdc2 (Tyr15)(#4539S), and
phosphorylated H2A.X (Ser139) (γ-H2A.X) (#2577S) from
Cell Signaling. Antibody to β-actin came from Sigma (St.
Louis, MO, USA). Finally, all these antibodies were de-
tected using the enhanced chemiluminescence kit ECL
(GE) and the compact darkroom ChemiDoc-It (UVP).
Immunofluorescence analysis
NALM-6 and BV-173 cells were seeded to poly-D lysine-
coated slides, fixed with 4 % PFA (paraformaldehyde), and
stained at 37 °C with a mouse anti-H2A.X-PhosphorylatedAlexa 647 conjugated antibody (BioLegend). Then, they
were treated with DAPI (4.6 diamidino-2-phenylindole;
Sigma Aldrich), and the slides were mounted with Mowiol
(Calbiochem). Images were acquired with wide field fluor-
escence microscope Olympus BX61 fully motorized driven
by Metamorph software, and the analysis was performed
using the freeware ImageJ software.
Gene expression profiling
Gene expression profiling on treated and untreated cells
(DMSO 0.1 %) after 24 h of exposure to PF-0077736 was
performed using Affymetrix GeneChip Human Gene 1.0
ST platform (Affymetrix Inc. Santa Clara, CA, USA) and
following manufacturers’ instructions. Raw data were nor-
malized by using the RMA algorithm and filtered. Genes
differentially expressed were selected by analysis of vari-
ance (ANOVA) (p value threshold =0.05) using the Partek
Genomics Suite software (Partek Incorporated Saint
Louis, MO, USA; http://www.partek.com). The most sig-
nificantly involved process networks were defined by the
Metacore software (GeneGo Inc., www.genego.com).
Cell cycle analysis
In order to evaluate the effect of PF-00477736 on cell
cycle progression, NALM-6, SUPB-15, RPMI-8402, and
BV-173 cell lines were seeded in a 24-well plate at 500,000
cell/1 ml with increasing concentrations of PF-00477736
(0.1, 0.5, and 1 μM for NALM-6 and SUP-B15; 0.05, 0.1,
and 0.2 μM for RPMI-8402 and BV-173). After 6 and
24 h, cells were harvested and fixed overnight using etha-
nol at 70 %. Then, cells were stained using PI/RNase
Staining Buffer according to the manufacturer’s instruc-
tion (BD Pharmingen), and the cell cycle profile was de-
tected using FACSCanto II instrument. The percentage of
the different cell cycle phases was performed using the
DNA cell-cycle analysis software for flow cytometry data,
ModFit LT (Verity).
In vivo studies
Experiments involving mice were performed in agree-
ment with Italian guidelines and after the approval of
the Institutional Review Board of the European Insti-
tute of Oncology. Leukemic mice were generated by a
single administration of the tumorigenic agent N-ethyl-
N-nitrosourea (Sigma, 50 mg/kg intraperitoneally).
Spleen cells from leukemic C57BL6/Ly5.2 mice were
injected intravenously (2 × 106 cells/mouse) into non-
irradiated, recipient C57BL6/Ly5.1 mice. PF-0077736
was administered intraperitoneally starting from day 3
after the transplant of leukemic cells. Mice received
doses of PF-0077736 (40 mg/kg each dose) every 3 days
for four treatments (q3dx4). Kaplan-Meyer rank test
was used to compare the survival rate between treated
and control mice.
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Additional file 1: Figure S1. Basal expression of Chk1 and Chk2 (mRNA
level) in the cell lines treated, the results are expressed as 2exp(-ΔΔCt)
(A). Schematic representation of the statistically significance of the ANOVA
multiple comparison test in which the basal expression of each cell lines is
compared to the value of the basal expression of all the other cell
lines (B). Figure S2. Oncomine expression analysis of Chk1 (A) and
Chk2 (B) levels between normal monunuclear cells (MNCs) from bone
marrow and different subtypes of leukemia (AML, B-ALL, T-ALL).
Figure S3. Apoptosis following treatment with PF-00477736 at 24
and 48 hours in B-ALL and T-ALL cells(A). Cell cycle analysis of RPMI-
8402, BV-173, SUP-B15 and NALM-6 cell lines treated for 24 hours
with increasing concentrations of PF-00477736 (B). Figure S4.
Western Blot analysis in all leukemia cell lines after exposure to
PF-00477736 (+) at the concentration closest the IC50 or DMSO
0.1 %(-) (A). Western Blot analysis of BV-173 and NALM-6 cell lines
treated with or without PF-00477736 (IC50) for 3, 6 and 9 hours (B). Figure
S5. Cell cycle_ESR1 regulation of G1/S transition: the top scored map (map
with the lowest p-value) based on the enrichment distribution sorted by
'Statistically significant Maps' set. Figure S6. Apoptosis and
survival_Granzyme A signaling: the second scored map (map with
the second lowest p-value) based on the enrichment distribution
sorted by 'Statistically significant Maps' set. Figure S7. DNA
damage_ATM/ATR regulation of G1/S checkpoint: the third scored
map (map with the third lowest p-value) based on the enrichment
distribution sorted by 'Statistically significant Maps' set. Figure S8.
Protein expression level of c-Jun in B-/T-ALL cell lines (A). Western
Blot analysis of normal MNCs and ALL MNCs after exposure to
PF-0047773(B). mRNA expression of CDK4, Chk2, GADD45a and PLK3
in B-/T-ALL cell lines treated with or without PF-00477736(IC50 value)
for 24 hours. The results are expressed as 2exp(-ΔΔCt)(C). (PPTX 2905 kb)
Additional file 2: Treatment resulted in a differential expression of
941 genes (p < 0.05). (PDF 256 kb)
Additional file 3: Enrichment analysis report: enrichment by GO
processes. (PDF 41 kb)
Additional file 4: Enrichment analysis report: enrichment by
process networks. (PDF 35 kb)
Additional file 5: Table S1. List of differentially expressed genes
between treated cells and their untreated counterpart with a false
discovery rate less than 0.05. Table S2. Main clinical and molecular
characteristics of ALL patients whose primary ALL samples have been
tested in vitro. Table S3. TP53 primer sequences. Table S4. Antibody
reactivity and sources as well as the antigen retrieval protocols, dilutions,
and revelation systems used in immunohistochemistry. (DOCX 28 kb)
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